Background-Oncogenic human papillomaviruses (HPV) are sexually transmitted and linked to several epithelial malignancies, but an association between HPV and colorectal neoplasia is not established. Previously, we reported a 3-fold increase in the odds of colorectal hyperplastic polyps associated with oncogenic HPV seropositivity in men, but detected no HPV DNA in colorectal tissues from these same men.
Introduction
Oncogenic human papillomavirus (HPV) genus alpha types 16, 18, and others, are sexually transmitted and causally associated with cervical cancer and other epithelial malignancies, including anal carcinomas (1) . Because the anal canal is contiguous with the rectum and colon, and colorectal cancer is an epithelial malignancy, the association between colorectal cancer or polyps and oncogenic HPV has been investigated in over 20 studies (2) . Some studies reported a positive association between HPV and colorectal neoplasia whereas others reported no association (2) .
Previously, we evaluated the association between oncogenic HPV and colorectal polyps, including adenomas and hyperplastic polyps (HPs) (3) . We detected no oncogenic HPV DNA in over 600 polyp and normal colorectal tissue samples. However, among men without previous polyps, we observed a 3-fold increase (95% confidence interval (CI): 1.1-7.9) in the odds of HPs associated with oncogenic HPV seropositivity (3), suggesting a possible sexually transmitted etiology for these lesions. To follow-up our prior results, we conducted a case-control study of HPs among men enrolled in the Minnesota Cancer Prevention Research Unit Polyp Prevention Study.
Materials and Methods

Study population
Details of this study population were previously described (4) . Briefly, participants were recruited prior to an elective colonoscopy for any indication at a gastroenterology practice in Minneapolis, Minnesota from 1991-1994. Eligible participants were 30-74 years old and residents of the Minneapolis/St. Paul metropolitan area with no history of colorectal polyps. Prior to colonoscopy, written informed consent and study questionnaires were completed, and a blood sample collected. Among men with blood samples and questionnaire data available, we selected all participants diagnosed with HPs but no other polyps (n=97), and all participants who were polyp-free at the colonoscopy (n=184).
Antibody assay
Plasma samples were tested for antibodies to HPV types 16, 18, 31, 33, 35, 45, 52, and 58, herpes simplex virus-2 (HSV-2), and hepatitis C virus (HCV) using a multiplex, bead-based Luminex assay (5) (6) (7) . For each HPV type, we used a bead set carrying the type-specific HPV L1 antigen. For HSV-2, the bead set included the protein domain of the membrane glycoprotein G (mgG) not shared with herpes simplex virus-1, and for HCV, we used two bead sets, one with the HCV core antigen and one with the NS3 antigen. For quality control, we used a bead set with the viral capsid (VP1) antigen of BK virus, a ubiquitous polyomavirus with almost universal positive antibody status (8) , and a bead set without antigens. Beads were differentiated and antibodies bound to each bead were quantified as median fluorescence intensity (MFI).
Statistical analyses
Seropositivity was determined using pre-specified, antigen-specific cutpoints (>400 MFI for HPV L1 antigens and >500 MFI for HSV-2 and HCV antigens). For HCV, a positive value for either the core or NS3 antigens was used as a marker of HCV seropositvity. We also included a variable for seropositivity to types 16 or 18 and a variable for seropositivity to any oncogenic HPV tested. We performed multivariable logistic regression to estimate the odds ratios (OR) and 95% confidence intervals (CI) for HPs by comparing seropositivity to each antigen in cases to polyp-free controls. Regression models included age, race, smoking status (never, former, current), education, body mass index (BMI), and usual alcohol consumption (drinks/week).
Power Calculation
Using Power (version 3.0, 1999, National Cancer Institute, Bethesda, MD) we calculated that, given our sample size and alpha=0.05, our study had 99% power to detect an OR ≥3, the point estimate from our prior study (3) .
Results
HP cases were more likely than controls to be former/current smokers and have a BMI ≥25 kg/m 2 ( Table 1 ). There was no association between HPs and antibodies to any of the viruses evaluated ( Table 2 ). For HPV, the adjusted OR for the association between seropositivity to any of the oncogenic HPV types evaluated and HPs was 0.84 (CI: 0.44-1.58); for HSV-2, OR=0.98 (CI: 0.48-1.99); and for HCV, OR=0.61 (CI: 0.11-3.26).
Discussion
In contrast to our prior study (3), antibodies to HPV were not associated with HPs in men without a history of polyps. Furthermore, there was no association between HPs in men and antibodies to two other infections that are transmitted sexually. These results suggest that specific sexually transmitted infections (and possibly sexual risk factors more generally) are not associated with HPs in men.
Our prior study of HPV and colorectal polyps included both sexes, HPs and adenomas, and participants with and without a history of colorectal polyps. Therefore, we previously included analyses for both adenomas and HPs, stratified by sex, and restricted to participants without a history of colorectal polyps. These multiple analyses increased the chance of a type I error. In our replication study, we selected an independent study population that included only men without prior polyps, and we excluded those with adenomas, greatly decreasing the chance of a type I error and illustrating the importance of following up provocative findings based on subgroup analyses with a rigorous, directed replication study. 
